Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Comment by eric40on Mar 31, 2021 7:36pm
214 Views
Post# 32919836

RE:RE:Welcome to the Big Leagues

RE:RE:Welcome to the Big LeaguesFrom the article,

That in turn should give them the firepower to attract more opportunities.

That is one more important factor about this deal beside the large increase in revenu over the next 2-3 years


Short term, since they will double the workforce, the administrations and sales fees will grow largely before the new revenu allow to be breakeven and eventualy very profitable IMO.

Let's see if they have enough cash and credit facility to avoid dilution before being cashflow positive with the revenu that will come from Redeska and those 2 new products kicks in. There suppose to be OK according to IR and they will adress this concern tomorrow morning in the CC

In any case, future looks bright more than ever and revenu should be multiple X for 2021 and the SP should follow accordingly.



<< Previous
Bullboard Posts
Next >>